PMID: 8443313Feb 1, 1993Paper

Use of paromomycin for treatment of cryptosporidiosis in patients with AIDS

Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
C J FichtenbaumW G Powderly

Abstract

Cryptosporidiosis in patients with AIDS often leads to a severe wasting illness that is difficult to treat. Recent reports suggest that paromomycin may be useful in the treatment of intestinal cryptosporidiosis. We reviewed our experience using paromomycin for the treatment of cryptosporidiosis in seven patients with AIDS. All patients received paromomycin (500 mg orally every 6 hours) for an average of 11.7 days. The mean follow-up period was 3.2 months. All patients had an initial response to paromomycin that was characterized by a decrease in frequency of diarrheal episodes, stabilization of body weight, and/or eradication of cryptosporidia from the stool. The mean number of diarrheal episodes decreased from 10.9 to 1.7 daily. Stabilization or increase in body weight was noted for five of seven patients, and eradication of oocysts was documented for three patients. Relapses or recurrences were noted for three patients. Treatment with paromomycin was well tolerated by all patients with the exception of two, who experienced nausea and abdominal discomfort. Thus, paromomycin appears to be a promising agent for treatment of acute cryptosporidiosis.

Citations

Jun 20, 2003·International Journal for Parasitology·R MeleE Pozio
Jul 14, 1999·Diagnostic Microbiology and Infectious Disease·C Franzen, A Müller
Aug 3, 2006·Nature Clinical Practice. Gastroenterology & Hepatology·Michael J G Farthing
Oct 26, 2000·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·R G HewittJ F Bender
Feb 15, 2001·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·R L GuerrantUNKNOWN Infectious Diseases Society of America
Jul 1, 1994·Antimicrobial Agents and Chemotherapy·R VerdonJ J Pocidalo
Jan 1, 1995·Antimicrobial Agents and Chemotherapy·R MancassolaC Chartier
Mar 1, 1994·Gut·J JerniganR D Pearson
Oct 1, 1994·Pediatric Annals·A Deveikis
Sep 1, 1996·Gastroenterology Clinics of North America·M F Heyworth
Jul 16, 2002·Memórias do Instituto Oswaldo Cruz·Marcelo Simão Ferreira, Aércio Sebastião Borges
Jun 15, 2006·Expert Review of Anti-infective Therapy·Simone M Cacciò, Edoardo Pozio
Mar 1, 1997·Journal of Travel Medicine·R Hashmey White Jr
Jan 1, 1995·The Annals of Pharmacotherapy·W W TanL I Lutwick
Oct 1, 1995·The Annals of Pharmacotherapy·R E Bessette, G W Amsden
Jan 1, 1996·International Journal of STD & AIDS·I M Hoepelman
May 1, 1995·International Journal of STD & AIDS·E D Ehrenpreis
Dec 1, 1996·Annals of Tropical Medicine and Parasitology·K M WoodsS J Upton
Dec 1, 1993·The Annals of Pharmacotherapy·L H DanzigerR M Novak
Jun 1, 1994·The Annals of Pharmacotherapy·D J Ritchie, E S Becker
Mar 1, 1997·Medicine·R HashmeyA C White
Feb 1, 1994·Alimentary Pharmacology & Therapeutics·H L DuPont
Jan 31, 2002·World Journal of Gastroenterology : WJG·Xian-Ming Chen, Nicholas F LaRusso
Jul 1, 1996·Revista Da Sociedade Brasileira De Medicina Tropical·H N StefaniA O Fernandes
Feb 11, 2000·Veterinary Parasitology·T Sréter, I Varga
Sep 26, 1997·Antimicrobial Agents and Chemotherapy·J R ForneyM C Healey
Oct 9, 1999·Clinical Microbiology Reviews·D P Clark
Jul 1, 1995·Clinical Microbiology Reviews·M Khaw, C B Panosian
Jul 28, 2009·Experimental Parasitology·Jean-François Rossignol

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.

Related Papers

Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
F BissuelC Trepo
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
M R WallaceJ A Newton
European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology
A ClavelJ Cuesta
© 2021 Meta ULC. All rights reserved